Literature DB >> 26298721

Oxidative stress induced by low-dose doxorubicin promotes the invasiveness of osteosarcoma cell line U2OS in vitro.

Seung Han Shin1, Young Joon Choi2, Hyewon Lee3, Han-Soo Kim4, Sung Wook Seo5.   

Abstract

Reactive oxygen species (ROS) are known to mediate doxorubicin (DOX)-induced apoptosis and are the major cause of DOX toxicity. We introduce a novel in vitro phenomenon of osteosarcoma (OS) cell line caused by low-dose DOX-induced oxidative stress. Human osteosarcoma cell line U2OS was used for the experiments. Hydrogen peroxide (H2O2) and the antioxidant compound N-acetylcysteine (NAC) were used to investigate the involvement of oxidative stress. In proliferation assays, low dose of DOX (below 200 nM) did not affect U2OS proliferation significantly for up to 48 h. In Matrigel(TM) invasion assay, DOX increased the invasiveness of U2OS at around 100 nM, which is a subclinical concentration. Quantitative real-time polymerase chain reaction and gelatin zymography showed increased MMP-9 expression and increased MMP-9 enzymatic activity, respectively, in the presence of DOX doses that increased the invasiveness of U2OS. H2O2, a representative source of ROS, also increased the invasiveness of U2OS as DOX did, with similar patterns. However, when the cells were pre-treated with NAC, no DOX- or H2O2-mediated increase of invasiveness or MMP-9 expression was evident. The results suggest that oxidative stress induced by low-dose DOX promotes the invasiveness of osteosarcoma cell line U2OS in vitro, through MMP-9 induction.

Entities:  

Keywords:  Doxorubicin; Invasiveness; MMP-9; Osteosarcoma; Oxidative stress; Reactive oxygen species

Mesh:

Substances:

Year:  2015        PMID: 26298721     DOI: 10.1007/s13277-015-3702-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

1.  ERK5 regulates invasiveness of osteosarcoma by inducing MMP-9.

Authors:  Sang-Min Kim; Hyewon Lee; Youn-Soo Park; Youbin Lee; Sung Wook Seo
Journal:  J Orthop Res       Date:  2011-12-29       Impact factor: 3.494

2.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors:  M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

3.  Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation.

Authors:  J Shapira; M Gotfried; M Lishner; M Ravid
Journal:  Cancer       Date:  1990-02-15       Impact factor: 6.860

4.  Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.

Authors:  R F Greene; J M Collins; J F Jenkins; J L Speyer; C E Myers
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

5.  Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis.

Authors:  W P Tsang; Sophia P Y Chau; S K Kong; K P Fung; T T Kwok
Journal:  Life Sci       Date:  2003-09-05       Impact factor: 5.037

6.  Regulation of cancer invasion by reactive oxygen species and Tks family scaffold proteins.

Authors:  Alissa M Weaver
Journal:  Sci Signal       Date:  2009-09-15       Impact factor: 8.192

7.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Authors:  Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh
Journal:  Nat Med       Date:  2012-10-28       Impact factor: 53.440

8.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.

Authors:  D A Scudiero; R H Shoemaker; K D Paull; A Monks; S Tierney; T H Nofziger; M J Currens; D Seniff; M R Boyd
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

9.  Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.

Authors:  H C A Graat; M A Witlox; F H E Schagen; G J L Kaspers; M N Helder; J Bras; G R Schaap; W R Gerritsen; P I J M Wuisman; V W van Beusechem
Journal:  Br J Cancer       Date:  2006-05-30       Impact factor: 7.640

10.  Osteosarcoma: evolution of treatment paradigms.

Authors:  Norman Jaffe; Ajay Puri; Hans Gelderblom
Journal:  Sarcoma       Date:  2013-05-27
View more
  5 in total

1.  Osteosarcoma tissue-engineered model challenges oxidative stress therapy revealing promoted cancer stem cell properties.

Authors:  Juan Tornín; Aranzazu Villasante; Xavi Solé-Martí; Maria-Pau Ginebra; Cristina Canal
Journal:  Free Radic Biol Med       Date:  2021-01-02       Impact factor: 7.376

2.  Anticancer effect of (S)-crizotinib on osteosarcoma cells by targeting MTH1 and activating reactive oxygen species.

Authors:  Xiangcheng Qing; Zengwu Shao; Xiao Lv; Feifei Pu; Feng Gao; Lei Liu; Deyao Shi
Journal:  Anticancer Drugs       Date:  2018-04       Impact factor: 2.248

3.  Alginate Oligosaccharide DP5 Exhibits Antitumor Effects in Osteosarcoma Patients following Surgery.

Authors:  Jiayu Chen; Yu Hu; Lirong Zhang; Yingjian Wang; Shichao Wang; Yanzi Zhang; Haiyan Guo; Degang Ji; Yingtao Wang
Journal:  Front Pharmacol       Date:  2017-09-12       Impact factor: 5.810

4.  The lack of functional DNMT2/TRDMT1 gene modulates cancer cell responses during drug-induced senescence.

Authors:  Dominika Bloniarz; Jagoda Adamczyk-Grochala; Anna Lewinska; Maciej Wnuk
Journal:  Aging (Albany NY)       Date:  2021-06-17       Impact factor: 5.682

5.  Synthesis of Novel Structural Hybrids between Aza-Heterocycles and Azelaic Acid Moiety with a Specific Activity on Osteosarcoma Cells.

Authors:  Gabriele Micheletti; Natalia Calonghi; Giovanna Farruggia; Elena Strocchi; Vincenzo Palmacci; Dario Telese; Silvia Bordoni; Giulia Frisco; Carla Boga
Journal:  Molecules       Date:  2020-01-18       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.